America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What types of cancer have shown responsiveness to AOH1996 in your research?
**Interview with Dr. Linda Malkas, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope Hospital**
**Editor:** Dr. Malkas, thank you for joining us today. Your research team at City of Hope Hospital has developed a groundbreaking drug called AOH1996 that targets solid tumors. Can you explain how this drug works?
**Dr. Malkas:** Thank you for having me. AOH1996 is designed to specifically target a variant of the PCNA protein that is crucial for DNA replication and tumor growth. Think of PCNA as a major hub in an airport that orchestrates the movement of planes—in our analogy, these planes are cancer cells. By targeting the mutated version of PCNA found in cancer cells, AOH1996 effectively disrupts their reproductive cycle, leading to selective cell death.
**Editor:** That sounds impressive. How was AOH1996 developed, and what types of cancer can it treat?
**Dr. Malkas:** The development of AOH1996 has been a journey of nearly two decades. We conducted extensive research on more than 70 cancer cell lines to assess its efficacy. The results indicate that it is effective against various types of cancer, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers.
**Editor:** What were the results of your studies on the drug’s effectiveness?
**Dr. Malkas:** In our studies, AOH1996 demonstrated a remarkable ability to selectively kill cancer cells. The molecule effectively disrupted the normal reproductive cycle of these cells without harming healthy tissues, which is a significant advancement in targeted chemotherapy.
**Editor:** What are the next steps in the research and development process for AOH1996?
**Dr. Malkas:** The next step is to move forward with clinical trials in humans. We hope to establish the safety and effectiveness of AOH1996 in patients, allowing us to take a major leap toward new treatment options for cancer patients.
**Editor:** It’s exciting to hear about these advancements. What message would you like to convey to patients and families affected by cancer?
**Dr. Malkas:** I want patients and their families to know that there is hope. Research is progressing rapidly, and we are committed to developing therapies that can provide better outcomes with fewer side effects. Our work is a testament to the dedication of scientists and the promising innovations we can achieve together.
**Editor:** Thank you, Dr. Malkas, for sharing your insights with us today. We look forward to following the progress of AOH1996 and your future research.
**Dr. Malkas:** Thank you for having me.
